Barclays’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-5,000
| Closed | -$25K | – | 7273 |
|
|
2016
Q4 | $25K | Buy |
5,000
+4,600
| +1,150% | +$23.6K | ﹤0.01% | 5529 |
|
|
2016
Q3 | $2K | Buy |
+400
| New | +$2.05K | ﹤0.01% | 6350 |
|
|
2016
Q2 | – | Sell |
-33,400
| Closed | -$167K | – | 7007 |
|
|
2016
Q1 | $167K | Sell |
33,400
-5,200
| -13% | -$36.3K | ﹤0.01% | 3966 |
|
|
2015
Q4 | $386K | Buy |
38,600
+23,100
| +149% | +$314K | ﹤0.01% | 3399 |
|
|
2015
Q3 | $279K | Sell |
15,500
-8,000
| -34% | -$154K | ﹤0.01% | 3857 |
|
|
2015
Q2 | $447K | Buy |
23,500
+4,300
| +22% | +$76.1K | ﹤0.01% | 3561 |
|
|
2015
Q1 | $326K | Sell |
19,200
-28,000
| -59% | -$470K | ﹤0.01% | 3970 |
|
|
2014
Q4 | $708K | Sell |
47,200
-19,800
| -30% | -$265K | ﹤0.01% | 3516 |
|
|
2014
Q3 | $804K | Buy |
67,000
+31,300
| +88% | +$446K | ﹤0.01% | 3550 |
|
|
2014
Q2 | $536K | Sell |
35,700
-7,100
| -17% | -$104K | ﹤0.01% | 3906 |
|
|
2014
Q1 | $556K | Sell |
42,800
-6,600
| -13% | -$103K | ﹤0.01% | 3848 |
|
|
2013
Q4 | $790K | Buy |
49,400
+3,900
| +9% | +$62.2K | ﹤0.01% | 3643 |
|
|
2013
Q3 | $728K | Buy |
45,500
+28,700
| +171% | +$424K | ﹤0.01% | 3695 |
|
|
2013
Q2 | $169K | Buy |
+16,800
| New | +$177K | ﹤0.01% | 5347 |
|
Other funds holding OSIR
Barclays's OSIR Position: Q2 2019 in Review
Barclays sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 82,690 shares — an estimated $1.57M sold.
Barclays first reported a position in OSIR in Q2 2013 and held it in 18 quarters. The position peaked at $1.57M in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Barclays reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Barclays sold 82,690 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1.57M.
- Barclays first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
- Barclays's Osiris Therapeutics, Inc. Common Stock position peaked at $1.57M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Barclays's 13F filing for Q2 2019, filed 14 Aug 2019.